Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver
Evonik is investing in a new GMP drug product manufacturing facility for lipid-based drug delivery in Vancouver, Canada. ... MORE
Evonik is investing in a new GMP drug product manufacturing facility for lipid-based drug delivery in Vancouver, Canada. ... MORE
At an extraordinary meeting, the Supervisory Board today appointed Dr. Claus Rettig to Evonik's Executive Board effective September 1, 2026, and appointed him Deputy Chairman. ... MORE
Adjusted EBITDA rises to €630 million in the second quarter ... MORE
Production has begun at the new hydrogen peroxide megaplant operated by Fuhua and licensed by Evonik in Leshan, Sichuan Province, China. With an annual capacity of 200 kilotons, the facility is one of the largest in the region for industrial-grade hydrogen peroxide (H₂O₂). ... MORE
Evonik has partnered with global antibody expression specialist evitria to offer a ready-to-use transient protein expression kit based on CHO cells for biopharmaceutical research and development. ... MORE
Evonik has begun production of a high-performance membrane at a new pilot plant in Marl, North Rhine-Westphalia. This membrane is a key enabler for the production of more cost-efficient green hydrogen. ... MORE